Paclitaxel: 361 Real Stories

361 stories match paclitaxel. 359 of them mention chemotherapy.

Megan-Claire, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II Invasive Lobular Carcinoma: Megan-Claire's Survivor Story

Patient Info: Megan-Claire, Female, Under 40 | Stage II

As of July 2023, Megan-Claire had completed chemotherapy, breast-conserving surgery with reconstruction/reduction, and 33 radiation rounds, and was living with long-term effects including neuropathy, scarring, fatigue, and radiation trauma; no recurrence or NED status was stated.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Lucinda, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Lucinda's Patient Story

Patient Info: Lucinda Rudolph, Female, 60s

As of June 2023, Lucinda was living well after treatment for locally advanced recurrent invasive lobular breast cancer, taking exemestane, receiving supportive care for neuropathy, and returning to MD Anderson every 6 months for checkups.

MD Anderson
OutcomeCare Ongoing
Carol, who was diagnosed with Breast CancerBreast Cancer

BRCA1 Breast Cancer: Carol's Survivor Story

Patient Info: Carol Arnhart

Biomarkers: BRCA1 mutation

She had a complete pathologic response to breast chemotherapy and later reported no evidence of breast cancer.

MD Anderson
OutcomeCancer-Free / NED
Carol, who was diagnosed with Stage I Ovarian CancerOvarian Cancer

Stage I BRCA1 Ovarian Cancer: Carol's Survivor Story

Patient Info: Carol Arnhart | Stage I

Biomarkers: BRCA1 mutation

After staging surgery and 6 rounds of carboplatin and paclitaxel, she reported no evidence of ovarian cancer.

MD Anderson
OutcomeCancer-Free / NED
Christine, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HER2-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine Elliott, Female, Under 40 | Stage III

Biomarkers: Estrogen receptor-positive; HER2 and progesterone receptor status not reported

As of May 2023, Christine was about 3 years from diagnosis and in survivorship after chemotherapy, lumpectomy, and radiation. She reported lasting physical and emotional effects but did not state a formal NED status.

YouTube — The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Stage IV Ovarian Cancer Complicated by Anti-Yo Cerebellar Degeneration

Patient Info: Anonymized, Female | Stage IV

Biomarkers: CA-125: 1767 kU/L; anti-Yo antibodies positive in serum and cerebrospinal fluid

Her anti-Yo paraneoplastic cerebellar degeneration progressed despite methylprednisolone and plasma exchange. Care became palliative, and she died 2 months after hospital admission.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage IIIC Ovarian Cancer Found During Preoperative Screening

Patient Info: Anonymized, Female | Stage III

Biomarkers: BRCA1 pathogenic variant on homologous recombination deficiency testing; germline BRCA1 pathogenic variant

At approximately 1 year after surgery, she was alive without evidence of recurrence while continuing olaparib and bevacizumab maintenance therapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Rare breast blood-vessel cancer (angiosarcoma) in a teenage girl

Patient Info: Anonymized, Female

Biomarkers: Testing for Li-Fraumeni syndrome and POT1 mutation was inconclusive; no inherited cancer predisposition was established

She remained in remission 3 years after diagnosis and continued annual MRI surveillance of the reconstructed and opposite breasts.

PubMed Central
OutcomeCancer-Free / NED
Lucy, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy E., Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

As of January 2023, Lucy had been told she was all-clear/cancer-free after chemotherapy, had undergone double mastectomy with staged reconstruction planning, and was continuing close oncology reviews every 3-4 months.

The Patient Story
OutcomeCancer-Free / NED
Anne, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer: Anne's Patient Story

Patient Info: Anne, Female, 50s | Stage II

As of 2023, Anne was receiving/continuing care for Stage II breast cancer after lumpectomy, paclitaxel chemotherapy, radiation therapy, and a targeted-therapy plan reduced to 9 rounds by insurance coverage.

Our Cancer Stories
OutcomeCare Ongoing
Diana, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Diana's Patient Story

Patient Info: Diana, Female, 40s | Stage III

As of 2023, Diana was receiving treatment for Stage III breast cancer after quadrantectomy, chemotherapy, radiation therapy, hormone therapy, unilateral oncological mammoplasty, and lymph-node removal.

Our Cancer Stories
OutcomeCare Ongoing
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Recurrent Malignant Ovarian Steroid Cell Tumor Treated With Multiple Therapies

Patient Info: Anonymized, Female

Biomarkers: PIK3CA, and ATM mutations; ER negative; PR negative

She experienced repeated pelvic and lung recurrences. Platinum-based treatment produced a complete PET-CT response and olaparib maintenance provided about 1 year without progression before a 5 mm lung recurrence was surgically removed.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Spread to the Sinuses, Eye Sockets and Skull

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive

Metastatic Site: ethmoid and frontal sinuses; both orbits; multiple…

At 1-year follow-up, the sino-orbital metastases had not progressed on neuroimaging, right-eye visual acuity remained good, and chemoradiotherapy had been tolerated without complication.

PubMed Central
OutcomeStable Disease / Care Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Treatment Caused Severe Circulation Problems in Her Fingers and Toes

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; ER-negative; PR-negative

The digital ischaemia improved after gemcitabine was stopped, without revascularisation, debridement or amputation, although a small necrotic fingertip area persisted at 3 months. Metastatic breast cancer treatment continued with further systemic lines after progression.

PubMed Central
OutcomeLiving With Cancer / Ongoing Treatment
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV PIK3CA Breast Cancer: Abigail's Patient Story

Patient Info: Abigail, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer with PIK3CA mutation and germline ATM mutation; later PD-L1 somatic change reported. HER2 not stated.

Metastatic Site: Bone, including femurs, spine, and humeri; later liver

As of October 2022, Abigail was living with Stage IV hormone-positive metastatic breast cancer after years of treatment, bone-dominant disease that later involved the liver, targeted therapies, genomic testing, and advocacy around clinical trials and patient research participation.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Cancer in Accessory Breast Tissue Under Both Arms in a Man

Patient Info: Anonymized, Male

Biomarkers: Left tumor: HER2-positive by gene amplification; ER-negative; PR-negative; Ki-67 70%; p53 staining 80%

After surgery removed both accessory-breast cancers, he continued with adjuvant paclitaxel, trastuzumab and radiation.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Triple-Negative Breast Cancer Recurring in Groin Lymph Nodes

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: right inguinal lymph node; right iliac/pelvic lymph…

Her condition deteriorated after 3 cycles of palliative capecitabine. She developed vomiting, headache and seizures concerning for brain metastases and died about 4 months after the groin metastasis was detected.

PubMed Central
OutcomeIn Memory
Christal, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Christal's Survivor Story

Patient Info: Christal Love, Female, Under 40 | Stage III

Biomarkers: hormone-positive; HER2-negative

After chemotherapy complications, surgery, radiation, later preventive removal of the other breast and reconstruction, Christal remained cancer-free for more than 5 years as of June 2022.

City of Hope
OutcomeCancer-Free / NED
A patient, who was diagnosed with Ovarian AdenocarcinomaOvarian Cancer

Recurrent Ovarian Cancer and Olaparib-Related Skin Toxicity

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Metastatic Site: peritoneum|liver

The latest chemotherapy was effective, and she was alive without signs of another recurrence at the last documented follow-up.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Severe Esophageal Narrowing After Chemotherapy for Breast Cancer

Patient Info: Anonymized, female, 60s

The breast tumor shrank slightly and was considered stable before mastectomy. Her major subsequent problem was persistent treatment-related esophageal narrowing that required nutritional support and later a removable esophageal stent.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

HER2-positive metastatic gastric cancer responding to trastuzumab deruxtecan rechallenge

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

After trastuzumab deruxtecan was restarted, his symptoms improved after the first cycle and imaging showed tumor shrinkage after 3 cycles. He was still receiving treatment without progression at the latest follow-up.

PubMed Central
OutcomeResponding Well